Greater accuracy across a wider range of detection
With cell-free DNA technology, noninvasive prenatal screening (NIPS) can provide healthcare providers and their patients a safe way to detect chromosomal abnormalities in high-risk pregnancies. Most NIPS tests are limited in which aneuploidies can detect, the types of pregnancies that can be analyzed and the reliability of data. WithNatal Advanced, you can expect more and know more from the results.
Appropriate for all high-risk pregnancies, including multiple gestations and IVF using donor egg.
Analyzes more chromosomal regions than most other NIPS to date.
Reports both common and rare fetal chromosomal abnormalities, from trisomies 21,18, and 13 to fetal sex aneuploidies and select copy number variants.
Provides clear, direct results with high sensitivity and specificity.
Low non-reportable rates.
MPSS technology* with GC correction has been validated in the largest-of-its-kind clinical study of 4,664 women with high-risk pregnancies. Validation study designed, analyzed and confirmed by independent investigators.
The test can be performed as early as the 10-week gestation.
|
Positive Results |
sensitivity |
Specificity |
|
210 of 212 trisomy 21 |
99.1% |
99.9% |
|
59 of 59 trisomy 18 |
>99.9% |
99.6% |
|
11 of 12 trisomy 13 |
91.7 % |
99.7% |
|
8 of 8 multiple gestations: 7 of trisomy 21 1 of trisomy 13 |
>99.9% detection rate |
|
|
Y chromosome |
99.4% accuracy |
|
|
25 of 26 combined sex aneuploidies |
96.2% |
99.7%
|
The validation characteristics of the QNatal Advanced assay are consistent with the data presented above for MPSS with GC correction.
With its ability to analyze more chromosomal regions than most other NIPS to date, ()Natal Advanced can detect the following chromosomal abnormalities.
QNatal Advanced examines cell-free fetal DNA in maternal circulation using Massively Parallel Shotgun Sequencing technology.
Enhanced Sequencing Series also available: provides excellent analytical performance across a wide dynamic range (3 Mb to 40 Mb) for the detection of microdeletions/duplications.
Results are reported as positive or negative. Other laboratories report risk scores or "suspected" results that are not always clear. QNatal Advanced has very low non-reportable rates, so you and your patients can count on test accuracy and avoid retesting or an unnecessary invasive procedure.
The American Congress of Obstetricians and Gynecologists (AGOG) recommends the use of noninvasive prenatal tests in women at increased risk of aneuploidy or as a follow-up test for women with a positive first- or second-trimester maternal serum screening result.
Specimen requirements:
